Lycopene effects for improved prostate health

Agro Food Industry Hi-Tech

Volumn 16, Issue 1, 2005, Pages 13-15

  Herzog, Angelika ^a   Wertz, Karin ^a,b  

^a DSM NUTRITIONAL PRODUCTS LTD   (Switzerland)

^b NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDEMOLOGY; LYCOPENE; PROSTATE HEALTH; TOMATO PRODUCTS;

CELLS; CONCENTRATION (PROCESS); HEATING; OXYGEN; PLANTS (BOTANY); PROTEINS; THERMODYNAMIC STABILITY; TUMORS;

HEALTH;

LYCOPERSICON ESCULENTUM;

EID: 17044399772     PISSN: 17226996     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Mills PK, Beeson WL, Phillips RL, Fraser GE: Dietary habits and breast cancer incidence among Seventh-day Adventists. Cancer 1989, 64:582-590
2. Giovannucci E: Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999, 91:317-331
3. Pohar KS, Gong MC, Bahnson R, Miller EC, Clinton SK: Tomatoes, lycopene and prostate cancer: a clinician's guide for counseling those at risk for prostate cancer. World J Urol 2003, 21:9-14
4. Mares-Perlman JA, Millen AE, Ficek TL, Hankinson SE: The body of evidence to support a protective role for lutein and zeaxanthin in delaying chronic disease. Overview. J Nutr 2002, 132:5185-5245
5. Bohm V, Bitsch R: Intestinal absorption of lycopene from different matrices and interactions to other carotenoids, the lipid status, and the antioxidant capacity of human plasma. Eur J Nutr 1999, 38:118-125
6. Gartner C, Stahl W, Sies H: Lycopene is more bioavailable from tomato paste than from fresh tomatoes. Am J Clin Nutr 1997, 66:116-122
7. Erdman JW, Jr., Bierer TL, Gugger ET: Absorption and transport of carotenoids. Ann N Y Acad Sci 1993, 691:76-85
8. Stahl W, Sies H: Uptake of lycopene and its geometrical isomers is greater from heat-processed than from unprocessed tomato juice in humans. J Nutr 1992, 122:2161-2166
9. Goralczyk R, Siler U: The Role of Lycopene in Health and Disease. Phytochemicals in Health and Disease. Edited by Fenwick R. New York, Marcel Dekker, Inc., 2003, pp 285-309
10. Ripple MO, Henry WF, Rago RP, Wilding G: Prooxidantantioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997, 89:40-48
11. Woodall AA, Lee SW, Weesie RJ, Jackson MJ, Britton G: Oxidation of carotenoids by free radicals: relationship between structure and reactivity. Biochim Biophys Acta 1997, 1336:33-42
12. Kleinman D, Roberts CT, Jr., LeRoith D, Schally AV, Levy J, Sharoni Y: Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75. Regul Pept 1993, 48:91-98
13. Pollak M: Insulin-like growth factors and prostate cancer. Epidemiol Rev 2001, 23:59-66
14. Siler U, Barella L, Spitzer V, Schnorr J, Lein M, Goralczyk R, Wertz K: Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. Faseb J 2004, 18:1019-1021
15. Herzog, A, Siler, U, Spitzer, V, Seifert, N, Denelavas, A, Buchwald Hunziker, P, Hunziker W, Goralczyk R, Wertz K: Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J 2004, epub Nov 15; doi: 10.1096/fj.04-1905.fje.
16. Bowen P, Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, Kim HS, Christov-Tzelkov K, van Breemen R: Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Med (Maywood) 2002, 227:886-893
17. Hwang ES, Bowen PE: Cell cycle arrest and induction of apoptosis by lycopene in LNCaP human prostate cancer cells. J Med Food 2004, 7:284-289
18. Obermuller-Jevic UC, Olano-Martin E, Corbacho AM, Eiserich JP, van der Vliet A, Valacchi G, Cross CE, Packer L: Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. J Nutr 2003, 133:3356-3360
19. Zhang LX, Cooney RV, Bertram JS: Carotenoids up-regulate connexin43 gene expression independent of their provitamin A or antioxidant properties. Cancer Res 1992, 52:5707-5712
20. Saez JC, Berthoud VM, Branes MC, Martinez AD, Beyer EC: Plasma membrane channels formed by connexins: their regulation and functions. Physiol Rev 2003, 83:1359-1400
21. Mehta PR Perez-Stable C, Nadji M, Mian M, Asotra K, Roos BA: Suppression of human prostate cancer cell growth by forced expression of connexin genes. Dev Genet 1999, 24:91-110
22. Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, Li YW, Banerjee M, Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood DP, Jr.: Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2001, 10:861-868
23. De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG: Human prostate cancer precursors and pathobiology. Urology 2003, 62:55-62
24. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET: Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001, 12:33-40
25. Brawley OW: Hormonal prevention of prostate cancer. Urol Oncol 2003, 21:67-72
26. Kucuk O: Chemoprevention of prostate cancer. Cancer Metastasis Rev 2002, 21:111-124
27. Geller J, Sionit L: Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride. J Cell Biochem Suppl 1992, 16H:109-112
28. Kwak MK, Egner PA, Dolan PM, Ramos-Gomez M, Groopman JD, Itoh K, Yamamoto M, Kensler TW: Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutat Res 2001, 480-481:305-315
29. Lee WH, Isaacs WB, Bova GS, Nelson WG: CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev 1997, 6:443-450
30. Nakayama M, Bennett CJ, Hicks JL, Epstein Jl, Platz EA, Nelson WG, De Marzo AM: Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 2003, 163:923-933
31. Breinholt V, Lauridsen ST, Daneshvar B, Jakobsen J: Doseresponse effects of lycopene on selected drug-metabolizing and antioxidant enzymes in the rat. Cancer Lett 2000, 154:201-210
32. Velmurugan B, Bhuvaneswari V, Burra UK, Nagini S: Prevention of N-methyl-N′-nitro-N-nitrosoguanidine and saturated sodium chloride-induced gastric carcinogenesis in Wistar rats by lycopene. Eur J Cancer Prev 2002, 11:19-26
33. Culig Z: Role of the androgen receptor axis in prostate cancer. Urology 2003, 62:21-26
34. El Sheikh SS, Domin J, Abel P, Stamp G, Lalani el N: Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia 2003, 5:99-109
35. Huynh HT, Alpert L, Laird DW, Batist G, Chalifour L, Alaoui-Jamali MA: Regulation of the gap junction connexin 43 gene by androgens in the prostate. J Mol Endocrinol 2001, 26:1-10
36. Temme A, Traub O, Willecke K: Downregulation of connexin32 protein and gap-junctional intercellular communication by cytokine-mediated acute-phase response in immortalized mouse hepatocytes. Cell Tissue Res 1998, 294:345-350
37. Lin D, Boyle DL, Takemoto DJ: IGF-l-induced phpsphorylation of connexin 43 by PKCgamma: regulation of gap junctions in rabbit lens epithelial cells. Invest Ophthalmol Vis Sci 2003, 44:1160-1168
38. Bradshaw SL, Naus CC, Zhu D, Kidder GM, D'Ercole AJ, Han VK: Alterations in the synthesis of insulin-like growth factor binding proteins and insulin-like growth factors in rat C6 glioma cells transfected with a gap junction connexin43 cDNA. Regul Pept 1993, 48:99-112